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Abstract
Background: Despite the significant amount of work being carried out to investigate the therapeutic potential of
docosahexaenoic acid (DHA) in Alzheimer’s disease (AD), the mechanism by which DHA affects amyloid-b precursor protein
(AbPP)-induced metabolic changes has not been studied.
Objective: To elucidate the metabolic phenotypes (metabotypes) associated with DHA therapy via metabonomic profiling
of an AD cell model using gas chromatography time-of-flight mass spectrometry (GC/TOFMS).
Methods: The lysate and supernatant samples of CHO-wt and CHO-AbPP695 cells treated with DHA and vehicle control were
collected and prepared for GC/TOFMS metabonomics profiling. The metabolic profiles were analyzed by multivariate data
analysis techniques using SIMCA-P+ software.
Results: Both principal component analysis and subsequent partial least squares discriminant analysis revealed distinct
metabolites associated with the DHA-treated and control groups. A list of statistically significant marker metabolites that
characterized the metabotypes associated with DHA treatment was further identified. Increased levels of succinic acid, citric
acid, malic acid and glycine and decreased levels of zymosterol, cholestadiene and arachidonic acid correlated with DHA
treatment effect. DHA levels were also found to be increased upon treatment.
Conclusion: Our study shows that DHA plays a role in mitigating AbPP-induced impairment in energy metabolism and
inflammation by acting on tricarboxylic acid cycle, cholesterol biosynthesis pathway and fatty acid metabolism. The
perturbations of these metabolic pathways by DHA in CHO-wt and CHO-AbPP695 cells shed further mechanistic insights on
its neuroprotective actions.
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Introduction
Alzheimer’s disease (AD) is an emerging public health concern
for the global aging population. AD is an irreversible, chronic
neurodegenerative disease, characterized predominantly by the
presence of neuritic plaques of amyloid beta (Ab) peptide and
neurofibrillary tangles (NFTs) in the brain. The exact etiology of
neurodegeneration is unknown but has been proposed to involve
the interplay of mitochondrial dysfunction, inflammation, oxida-
tive stress, excitotoxicity and NFT formation. To date, there is no
disease-modifying treatment for AD. Recent evidence has
suggested the potential advantages of polyunsaturated fatty acids
(PUFAs) in AD, triggering questions on the contribution of diet in
the management of this devastating disorder [1,2]. PUFAs are
bioactive molecules with diverse physiological functions ranging
from its contribution in cell structure to signal transduction.
Amongst the omega-3 (n23) PUFAs, docosahexaenoic acid (DHA)
has been found to be the most abundant in the mammalian brain,
constituting about 8% of its dry weight [3]. It plays a key role in
memory, neuroprotection and vision and displays inflammation
resolving properties [4]. However, DHA levels have been found to
be significantly decreased in serum and neuronal membranes of
AD patients as compared to healthy controls [5,6], suggesting a
possible role of DHA in the intervention of AD. Based on the same
hypothesis, lipidomics-based approaches have identified neuro-
protectin D1, resolvins and maresin as the potent metabolites of
DHA having anti-inflammatory and neuroprotective effects [4,7].
It has also been demonstrated that DHA and these metabolites are
efficacious in reducing Ab plaque burden and protecting against
learning impairment in animal models [8–11]. In view of the
potential therapeutic benefits associated with DHA, there is an
impetus to elucidate its role in preventing AD.
Impaired mitochondrial functions and hypometabolism of the
neuronal cells have been characterized as neuropathological
hallmarks of AD. Accumulation and deposition of amyloid
precursor protein (AbPP) and its cleaved fragment, Ab, have
been implicated in the inhibition of various mitochondrial
enzymatic activities and for perpetration of oxidative stress-
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mediated damages [12–15]. AbPP localizes within the mitochon-
drial membranes and causes disruption of mitochondrial homeo-
stasis and functioning of the electron transport chain (ETC)
[12,16–18]. All these mitochondrial damages ultimately prevent
the neuronal cells from functioning normally, leading to neuronal
cell death. While the anti-inflammatory role of DHA has been
investigated, its effect against AbPP-induced metabolic distur-
bances has not been studied. The aim of this study was to elucidate
the mechanism of action of DHA in mitigating AbPP-induced
metabolic perturbations by characterizing and comparing the
metabotypes of DHA-treated and untreated wild type and AbPP-
associated cells.
The quantitative measurement of metabolites and their
perturbations offer insights into disease processes and pharmaco-
logical responses to therapeutic interventions. Gas chromatogra-
phy time-of-flight mass spectrometry (GC/TOFMS) techniques
have been well established and widely applied for the non-targeted
profiling of endogenous metabolites [19]. Coupled to the chemical
library databases and chemometric data analysis, GC/TOFMS-
based metabonomics facilitates detection of the metabolic fluxes
related to pharmacological interventions.
To address the aim of this study, a global metabonomics
profiling of the medium and lysate of DHA- and vehicle-treated
Chinese hamster ovary wild type (CHO-wt) cells and AbPP695-
transfected CHO (CHO-AbPP695) cells was performed using the
GC/TOFMS metabonomics. Our findings demonstrate for the
first time that DHA plays a role in mitigating AbPP-induced
impairment in energy metabolism and inflammation and shed
preliminary mechanistic insights on its neuroprotective effects.
Materials and Methods
Materials
Dulbecco’s modified eagle’s medium (DMEM), succinic acid,
glycine, citric acid, malic acid, mefenamic acid, silanization
solution (5% dimethyl dichlorosilane in heptane) and sodium
sulfate were purchased from Sigma-Aldrich (St Louis, MO, USA).
Docosahexaenoic acid (DHA) and arachidonic acid were obtained
from Cayman Chemical Co. (Ann Arbor, MI, USA). Zeocin was
purchased from Invitrogen (Carlsbad, CA, USA). Fetal bovine
serum (FBS) was obtained from Thermo Scientific Hyclone
(Logan, UT, USA). N-Methyl-N-(trimethylsilyl)trifluoroacetamide
(MSTFA) with 1% trimethylchlorosilane (TMCS) and 2%
methoxamine hydrochloride in pyridine (MOX reagent) were
purchased from Pierce (Rockford, IL, USA). Pyruvate dehydro-
genase assay kit was purchased from Assay BioTech (Sunnyvale,
CA, USA). Ultra-pure grade phosphate buffer saline (PBS) was
obtained from 1st Base Private Limited (Singapore). Dimethyl
sulfoxide (DMSO), toluene and methanol were purchased from
MP Biomedicals (Santa Ana, California, USA). Analytical grade
reagents were used for all the work.
Cell Culture
CHO-wt and CHO-AbPP695 cells were kindly provided by
Associate Professor Gavin S. Dawe (Department of Pharmacology,
Yong Loo Lin School of Medicine, National University of
Singapore) [20] and cultured and maintained in DMEM medium
supplemented with 10% FBS, 10 U/mL penicillin G, 100 mg/mL
streptomycin and 0.4 mg/mL zeocin for CHO-AbPP695 cells, in
humidified atmosphere at 37uC containing 5% CO2.
Western Blotting Analysis
Western blotting was used to examine the expression of AbPP
gene in CHO-wt and CHO-AbPP695 cells. Both the cell types
were seeded at a density of 16 105 cells/2 mL of medium in 6
well plates. 24 h post-seeding the cells were harvested and lysed in
lysis buffer containing 1% Triton with protease inhibitor (Roche,
Mannheim, Germany). Protein concentration was determined by
Bradford protein assay (Sigma Chemical Co., St Louis, MO,
USA). 30 mg of protein lysates were then loaded in 10–15%
polyacrylamide gel, prepared using 30% acrylamide-bisacrylamide
(BioRad, Hercules, CA, USA). The separated proteins were
subsequently blotted onto nitrocellulose membranes (Bio-Rad,
Hercules, CA, USA) and blocked overnight at room temperature
in tris-buffered saline containing 0.1% (v/v) Tween 20 and 5% (w/
v) fat-free dry milk, followed by incubation with the anti-APP
primary antibody (Merck KGaA, Darmstadt, Germany). Primary
incubation was followed by incubation with secondary antibody
after which the membranes were washed and incubated with the
West Femto or West Pico luminal/enhancer solution and stable
peroxide solution (Pierce, Rockford, IL, USA) before being
exposed to an X-ray film (ThermoFisher Scientific, Waltham,
MA, USA). The exposed films were subsequently processed using
X-ray developing machine (Konica Minolta, Tokyo, Japan). All
the experiments were performed at least in triplicates.
Ab40 ELISA Immunoassay
Cells were seeded at a density of 16105 cells/2 mL of medium
in 6 well plates. 24 h post-seeding the cells were treated with
25 mM DHA or vehicle-control and the conditioned medium was
collected from the cells after 24 and 48 h treatment duration. The
collected conditioned medium was centrifuged and the cell-free
supernatant was used for Ab40 ELISA immunoassay using
BetaMarkTM x-40 ELISA Kit (Covance Inc., NJ, USA) as per
manufacturer’s instructions.
Sample Preparation and Derivatization
Cells were seeded at a density of 16105 cells/2 mL of medium
in 6 well plates. 24 h post-seeding, 25 mM DHA was administered
to the cells and DMSO (at a final concentration of 0.1% v/v) was
used as the vehicle control. The optimal in vitro concentration of
DHA was selected based on the lack of observed toxicity and no
less than 80% cell survival in both the cell types. Treatment with
both DHA and DMSO was terminated after 24 h by harvesting
the culture medium and washing the cells twice with ice-cold PBS.
The collected culture medium was centrifuged and the cell-free
supernatant was stored immediately at 280uC until further
analysis. After quenching the metabolism with 1 mL ice-cold
methanol, cells were collected and stored at 280uC until further
sample preparation. Six independent biological replicates were
examined for each treatment group and all the samples were
subjected to extraction process to collect cell free supernatants
(supporting information – Text S1). The collected supernatants of
both the medium and the lysate samples were then concentrated to
complete dryness at 50uC under a gentle stream of nitrogen gas
using the TurboVap LV (Caliper Life Science, Hopkinton, MA,
USA), followed by an additional drying step after addition of
100 mL of anhydrous toluene (dried over anhydrous sodium
sulfate) to ensure complete removal of water. The dried extract
were then subjected to methoximation using 50 mL of MOX
reagent (2 h at 60uC), followed by trimethylsilyl (TMS) derivati-
zation using 100 mL of MSTFA with 1% TMCS as catalyst (1 h at
60uC). The formed TMS derivatives were cooled to room
temperature (2461uC) and transferred to the autosampler vials
for GC/TOFMS analysis.
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GC/TOFMS Conditions
GC/TOFMS analysis was performed on an Agilent 7890A Gas
Chromatography (Agilent Technologies, Santa Clara, CA, USA)
coupled to a PEGASUS 4D Time-of-Flight Mass Spectrometer
(LECO Corporation, St. Joseph, MI, USA). The primary column
used was a DB-1 GC column (Agilent Technologies) of internal
diameter of 250 mm, length of 23 m and film thickness of
0.25 mm. Helium was used as the carrier gas at a flow rate of
1 mL/min. The injection volume was 1 mL. A splitless injection
was used for the cell media while a split ratio of 1:2 was used for
the cell lysate. The optimized GC/MS front inlet and ion source
temperatures were 250 and 200uC, respectively. The oven
temperature was kept at 70uC for 20.0 min, increased to 250uC
at 8uC/min and finally to 300uC at 40uC/min where it remained
for 6 min. The transfer line was maintained at 250uC. The MS
was operated using an electron impact (EI) ionization source at 2
70 eV and a detector voltage of 1800 V. The MS data were
acquired in scan mode over the range m/z 50–600 at a rate of 15
spectra/s. Peaks with signal-to-noise (S/N) ratio lower than 100
were rejected. Quality control (QC) samples were prepared by
randomly pooling 40 mL from each of the six medium samples of
the control group Alkane series C8–C40 and fatty acid methyl
esters (FAME) (C8– C28) standards were analyzed with the same
GC program for calculation of the retention index of the
metabolites. LECO ChromaTOF software (version 4.21, LECO
Corporation, St. Joseph, MI, USA) was used for chromatogram
acquisition, peak deconvolution, analyte alignment and prelimi-
nary analyte identification by the National Institute of Standards
and Technology (NIST) library (Wiley registry, NJ, USA), Fiehn
library and internal spectral libraries. Based on the library
matching, peaks with similarity index of more than 60% were
given putative metabolite identities.
Multivariate Data Analysis and Metabolite Identification
The peaks were normalized to the total integral area prior to
chemometric and statistical data analysis. All processed data were
mean centered and scaled to unit variance during chemometric
data analysis. Principal component analysis (PCA) and partial least
Figure 1. Model validation for CHO-wt and CHO-AbPP695 cells and effect of DHA on Ab40 release. (A) Conditioned medium was collected
from CHO-wt and CHO-AbPP695 cells with and without DHA treatment and subjected to ELISA immunoassays for Ab40. There was negligible release of
Ab40 from CHO-wt cells as compared to CHO-AbPP695 cells at 24 and 48 h. A significant decrease was observed in the release of Ab40 in CHO-AbPP695
cells after treatment with 25 mM DHA for 24 h and 48 h. #p,0.001 as compared to CHO-wt vehicle treated cells, wp,0.05 compared to CHO-AbPP695
24 h vehicle treatment and 1p,0.001 as compared to CHO-AbPP695 48 h vehicle treatment. Analysis was done via ANOVA with Bonferroni’s post-hoc
analysis. (B) Western blot analysis of the cell lysates confirm AbPP695 plasmid overexpression in CHO-AbPP695 cells compared to CHO-wt.
doi:10.1371/journal.pone.0090123.g001
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squares and discriminant analysis (PLS-DA) were employed to
process the acquired and normalized data using SIMCA-P+
software (version 11, Umetrics, Umea˚, Sweden). PCA score plots
were used for observing the clustering trend among the samples as
well as to detect and exclude outliers. After exclusion of outliers,
medium and lysate samples were further subjected to PLS-DA for
identifying models that differentiated groups or classes. The
validity of the model was checked by performing 100 permutation
tests. The criteria for model validity are as follows. First, all the Q2
values on the permuted data set must be lower than the Q2 value
Figure 2. Overlay of GC/TOFMS chromatograms. (A) Representative GC/TOFMS chromatogram of DHA-treated and vehicle-treated CHO-
AbPP695 cells – lysate (L) and medium (M) samples (B) Representative chromatogram demonstrating discriminatory metabolites between vehicle-
treated and DHA-treated CHO-wt cells and CHO-AbPP695 cells.
doi:10.1371/journal.pone.0090123.g002
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on the actual data set. Second, the regression line in validation plot
(line joining the actual Q2 point to the centroid of the cluster of
permuted Q2 values) must demonstrate a negative intercept on the
y-axis. The validated models were subsequently utilized for
identifying unique metabotypes associated with the DHA- and
vehicle-treated groups. Variable importance in the projection
(VIP) cutoff value was set as 1.00. Statistical comparison of
discriminant metabolite levels between different groups was
carried out using independent t-test with Welch’s correction;
metabolites with a p-value of less than 0.05 being considered to be
statistically significant. These putative marker metabolites were
then cross-referenced against the Golm Metabolite Database
(GMD) [21] and the Human Metabolome Database (HMDB)
[22]. Identities of these metabolites were further ascertained by
comparing their mass spectra and retention indices with that of
commercially available reference standards Lastly, the Kyoto
Encyclopaedia of Genes and Genomes (KEGG) [23] database was
used for the interpretation of the metabolic pathways of the
identified marker metabolites. Difference in the levels of metab-
olite between the treatment group was assessed by fold change
values, where fold change = CHO2AbPP695(treatment)/CHO2
wt(treatment) and values .1 and ,1 represented higher and lower
metabolite levels observed in that treatment group, respectively.
Pyruvate Dehydrogenase Enzyme Assay
Both CHO-wt and CHO-AbPP695 cells were seeded at a density
of 1.56106/10 mL in a T75 flask followed by treatment with either
25 mM DHA or DMSO as vehicle control. The cells were
harvested 24 h post treatment and lysed in lysis buffer containing
1% Triton with protease inhibitor. Each cell lysate mixture was
centrifuged at 13000 g for 10 min at 4uC and protein concentra-
tion of the soluble extract was determined by Bradford protein
assay. An aliquot of the supernatant was diluted with the lysis
buffer to achieve a protein concentration of 400 mg/mL for each
sample. The assay was conducted as per the manufacturer’s
instructions with the final enzyme activity being assessed by
measuring the reduction of NAD+ to NADH at 340 nm using
InfiniteH 200Pro spectrophotometer (Tecan, Crailsheim, Ger-
many). Pyruvate dehydrogenase (PDH) enzyme concentration






Figure 3. PLS-DA score plot and validation plot for lysate samples. (A) PLS-DA score plot of vehicle-treated CHO-wt and CHO-AbPP695 lysate
samples (R2X = 0.474; R2Y = 0.985; Q2 (cum) = 0.808; LV = 2); (B) Validation plot of the PLS-DA model obtained from 100 permutation tests for vehicle-
treated lysate samples; (C) PLS-DA score plot of DHA-treated CHO-wt and CHO-AbPP695 lysate samples (R
2X = 0.645; R2Y = 0.993; Q2 (cum) = 0.971;
LV = 2); (D) Validation plot of the PLS-DA model obtained from 100 permutation tests for DHA-treated lysate samples.
doi:10.1371/journal.pone.0090123.g003
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Statistical analysis was done via ANOVA with Bonferroni’s




AbPP are transmembrane glycoproteins that exist in three
major isoforms, 770, 751 and 695, of which the 695 fragment
containing 695 amino acids is predominantly expressed in
neuronal cells [24]. Various in-vitro AD cell models have been
developed overexpressing AbPP695 fragment for AD studies
including CHO-AbPP695 [25–29]. To validate our cell model,
western blot analysis was performed and confirmed the overex-
pression of AbPP695 protein in CHO-AbPP695 cells compared to
the parental CHO-wt cells (Figure 1A). On the other hand, ELISA
immunoassays showed that Ab40 is released significantly only in
the conditioned medium of CHO-AbPP695 cells, even after 48 h
(Figure 1B). These results established the validity of our cell model
for subsequent metabolomic analysis.
GC/TOFMS Metabolic Profiling
Based on the survival curve (supporting information - Figure
S1), 25 mM dose of DHA was selected for carrying out further
analysis as it resulted in no significant toxicity and no less than
80% cell survival in both the cell types. Representative GC/
TOFMS chromatogram of medium and lysate samples of DHA-
and vehicle- treated CHO-AbPP695 cells is shown in Figure 2. A
similar representative GC/TOFMS chromatogram of medium
and lysate samples of DHA- and vehicle- treated CHO-wt cells is
shown in supporting information - Figure S2. Chemometric data
analysis revealed a distinct clustering trend between CHO-wt and
CHO-AbPP695 cells treated with DHA and vehicle control in both
the lysate and medium samples. For lysate samples, unsupervised
PCA scores plots showed differences between the two cell types in
vehicle-treated (R2X = 0.578 and Q2 (cum) = 0.295) and DHA-
treated groups (R2X = 0.655 and Q2 (cum) = 0.432). A similar
clustering was observed for medium samples in vehicle-treated
(R2X = 0.990 and Q2 (cum) = 0.114) and DHA-treated groups
(R2X = 0.681 and Q2 (cum) = 0.459).
Subsequent supervised PLS-DA model uncovered a list of
putative marker metabolites that were significantly different (p,
0.05 for T-test with Welch’s correction) and characterized the
metabotypes associated with DHA treatment effect (Figure 3 and
4). PLS-DA model was optimized with 2 latent variables (LV) for
lysate samples; vehicle-treated (R2X = 0.474, R2Y = 0.985 and Q2
(cum) = 0.808) and DHA-treated groups (R2X = 0.645,
R2Y = 0.993 and Q2 (cum) = 0.971), whereas model for medium
Figure 4. PLS-DA score plot and validation plot for medium samples. (A) PLS-DA score plot of vehicle-treated CHO-wt and CHO-AbPP695
medium samples (R2X = 0.679; R2Y = 0.994; Q2 (cum) = 0.929; LV = 3); (B) Validation plot of the PLS-DA model obtained from 100 permutation tests for
vehicle-treated medium samples; (C) PLS-DA score plot of DHA-treated CHO-wt and CHO-AbPP695 medium samples (R
2X = 0.745; R2Y = 0.992; Q2
(cum) = 0.885; LV = 3); (D) Validation plot of the PLS-DA model obtained from 100 permutation tests for DHA-treated medium samples.
doi:10.1371/journal.pone.0090123.g004
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samples was optimized with 3 LV; vehicle-treated (R2X = 0.679,
R2Y = 0.994 and Q2 (cum) = 0.929) and DHA-treated groups
(R2X = 0.745, R2Y = 0.992 and Q2 (cum) = 0.885). All the PLS-
DA models were found to be valid with no overfitting of data
based on the criteria of the permutation test. A list of all the
identified marker metabolites is summarized in supporting
information - Table S1. A list of discriminant marker metabolites
that have biological relevance in AD and significantly differenti-
ated DHA-treated and vehicle-treated groups in PLS-DA model
for both CHO-wt and CHO-AbPP695 cell types is summarized in
Table 1.
From Figure 1 and Table 1, we can see that even before
sufficient release of Ab40 in the culture medium (24 h versus 48 h),
AbPP induced metabolic changes in CHO-AbPP695 cells as
compared to CHO-wt cells. HMDB and KEGG databases were
used to elucidate the pathways that were associated with the
identified marker metabolites. With DHA treatment, the levels of
citric acid, malic acid and DHA were found to be elevated while
that of arachidonic acid, cholesta-3, 5-diene and zymosterol were
found to be significantly lowered in the lysate samples (Table 1).
These perturbed metabolites were found to correlate with
metabolic pathways of the TCA cycle (citric acid and malic acid),
cholesterol metabolism (zymosterol and cholesta-3, 5-diene) and
fatty acid biosynthesis (DHA and arachidonic acid). Similarly, in
medium samples, the levels of glycine, malic acid and succinic acid
were found to be elevated in DHA-treated groups. The metabolic
networks for these metabolites were correlated with specific
metabolic pathways of tricarboxylic acid cycle (TCA) (succinic
acid and malic acid) and amino acid metabolism (glycine). As
temporal longitudinal metabolic flux measurements (fluxomics
experiments) had not been performed in this study, neither the
relationships between the lysate versus medium marker metabo-
lites nor the rates of metabolic reactions in biological systems could
be determined. Table 2 summarizes the findings about the marker
metabolites, their associated metabolic pathways and their
biological significance in AD. Our findings suggested that DHA
Table 1. Discriminatory marker metabolites identified from medium and lysate samples of DHA-treated and vehicle-treated CHO-
wt and CHO-AbPP695 cells.





CHO-wt CHO-AbPP695 CHO-wt CHO-AbPP695
Citric acida lysate TCA 1844.5 7.560.9 8.463.3* 1.12 16.661.5 33.062.4* 1.99
Malic acida lysate TCA 1501.6 20.561.5 21.661.3ns 1.05 16.660.9 25.361.7* 1.52
DHAa lysate Fatty acid 2552.3 3.261.4 2.560.7* 0.79 3.560.2 4.560.3* 1.28
Arachidonic acida lysate Fatty acid 2352.8 3.160.3 3.560.4* 1.17 3.260.1 2.760.3* 0.85
Zymosterolb lysate Steroid 3170.0 4.360.4 7.660.9* 1.76 4.260.3 6.660.7* 1.59
Cholesta-3,5-dieneb lysate Steroid 2885.6 3.060.3 3.160.4 ns 1.05 3.060.4 1.560.5* 0.52
Succinic acida medium TCA 1305.9 3.260.5 3.560.1ns 1.09 3.460.3 4.160.3* 1.20
Malic acida medium TCA 1501.6 1.360.1 1.260.3ns 0.92 1.460.1 1.660.1* 1.17
Glycinea medium Amino acid 1316.1 80.8620.9 102.1629.4ns 1.30 181.4658.3 284.6647.6* 1.56
aMetabolite identification using standard compound.
bMetabolite identification using NIST library search.
cNormalized peak area values expressed as mean 6 S.E.M.
dFold change (D): CHO-AbPP695 (treatment)/CHO-wt (treatment).
*p,0.05 and ns not significant when calculated using the independent t-test with Welch’s correction for normalized peak area of CHO-AbPP695 cells compared to CHO-
wt cells for respective treatment groups.
Abbreviations: DHA – docosahexaenoic acid, TCA – tricarboxylic acid.
doi:10.1371/journal.pone.0090123.t001
Table 2. Metabolites, their associated metabolic pathways and biological relevance in AD.
Metabolitesa Metabolic pathwayb Biological relevance in AD
Citric acid (Q) TCA cycle Deregulation of TCA cycle, hypometabolism and increased oxidative damages
Succinic acid (Q) TCA cycle Deregulation of TCA cycle, hypometabolism and increased oxidative damages
Malic acid (Q) TCA cycle Deregulation of TCA cycle, hypometabolism and increased oxidative damages
Glycine (Q) Amino acid metabolism Required for synthesis of heme which is essential for functioning of electron transport chain
Zymosterol (q) Steroid biosynthesis Increased risk of formation and deposition of amyloid beta plaques from APP
Arachidonic acid (q) Eicosanoid biosynthesis Generation of pro-inflammatory and inflammatory mediators in AD
DHA (Q) Fatty acid biosynthesis Affects neuroprotection, successful aging, memory and inflammation resolving properties
aMetabolites are grouped together on the basis of their biological relevance. (q) elevated in AD and (Q) reduced in AD.
bRelated to metabolites using KEGG database.
Abbreviations: DHA – docosahexaenoic acid, TCA – tricarboxylic acid.
doi:10.1371/journal.pone.0090123.t002
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possibly acts by mitigating AbPP-induced deregulations in TCA
cycle, steroid and fatty acid biosynthesis.
Pyruvate Dehydrogenase Enzyme Assay
PDH is a rate limiting enzyme connecting the glycolysis and
TCA cycle and is found to be significantly decreased in AD
patients. Similarly, as seen in Figure 5, PDH enzyme concentra-
tion (mU/mL) was observed to be significantly lower in vehicle
treated CHO-AbPP695 compared to CHO-wt cells (50.365.9 vs.
80.567.1, ***p,0.001) in our study. This decrease in PDH
enzyme activity in CHO-AbPP695 confirmed the involvement of
AbPP in perturbing mitochondrial enzymatic activities and
provided an additional validation for the use of these cells as
surrogate models for the diseased and healthy patients. DHA
treatment for 24 h increased the enzyme concentration in both
CHO-wt (96.162.2) and CHO-AbPP695 (72.167.1) cells as
compared to their respective vehicle controls. This increase in
enzyme concentration in DHA-treated CHO-AbPP695 cells was
statistically significant as compared to vehicle-treated CHO-
AbPP695 cells (72.167.1 vs. 50.365.9, **p,0.01).
Effect of DHA on Ab40 Release
Cleavage of AbPP by b- and c-secretases yields numerous Ab
fragments, of which Ab40 and Ab42 are the most toxic. Among the
two, Ab40 has been found to be 10-fold higher in abundance than
Ab42 in patients with sporadic AD [30]. As reported by other
studies [31–33], DHA treatment has been shown to reduce the
release of Ab from its precursor, AbPP. In order to evaluate the
biological effects of DHA, we also undertook a similar experiment
wherein we evaluated the effect of DHA on the release of Ab40
from CHO-AbPP695 cells. As seen from Figure 1B, release of Ab40
was significantly higher at both 24 and 48 h time duration as
compared to CHO-wt cells, with the release at 48 h time duration
being comparatively higher than that at 24 h. DHA treatment at
25 mM concentration was able to decrease the release of Ab40
from CHO-AbPP695 cells at both 24 and 48 h treatment durations
by approximately 50%. In addition to the metabolomics data, this
result further corroborated the effect of DHA in reducing AbPP
mediated release of Ab peptides and the ensuing toxic damages to
the cells.
Discussion
Mitochondrial dysfunctions and associated energy hypometab-
olism have been considered as one of the important factors
contributing to the etiology of AD. Significant amount of work has
been done by various research groups showing the deleterious
effects of Ab on the mitochondrial activity. However, it has been
suggested recently that AbPP, the parent precursor to Ab, is toxic
and affects cellular metabolic activities. Trafficking of AbPP in the
mitochondrial matrix has been reported to impair functions of
various mitochondrial enzymes and leading to disturbances in
energy metabolism [13,34]. Amongst the affected enzymes of
TCA cycle, activity of a-ketoglutarate dehydrogenase, pyruvate
dehydrogenase and isocitrate dehydrogenase have been reported
to be markedly decreased in autopsied brains of AD patients while
the activity of succinate dehydrogenase and malate dehydrogenase
have been shown to be markedly increased [35]. These enzyme
alterations result in a reduction of succinyl CoA via its rapid
conversion to other metabolites that in turn reduces the
production of heme, a porphyrin molecule necessary for main-
taining the integrity of the ETC. This net decrease in the
production of ATP molecules establishes a state of hypometabo-
lism and oxidative stress in an AD brain.
Based on the results of pre-clinical and clinical studies, the
therapeutic effects of DHA and its isolated metabolites in
mitigating Ab- induced neurodegeneration, memory impairment
and inflammation have been established [10,11,36–39]. DHA has
also been shown to reduce the generation of Ab from its precursor
AbPP [31] and we have observed similar results in our study.
Through this study we have attempted to further characterize the
mechanism by which DHA mitigates AbPP-induced metabolic
changes by profiling the metabotypes associated with DHA-
treated and untreated wild type and AbPP695 cell models.
Effect of DHA on AbPP Impaired Energy Metabolism
Pathways
GC/TOFMS characterization of CHO-wt and CHO-AbPP695
at 24 h yielded distinct metabotypes associated with the DHA-
treated CHO-AbPP695 cells. With DHA treatment, we found
elevated levels of citric acid, succinic acid and malic acid in CHO-
AbPP695 cells suggesting a possible mitigation of AbPP-perturbed
TCA enzyme activities commonly observed in AD patients.
Upregulation of the decreased PDH enzyme level in CHO-
AbPP695 cells to the basal level of CHO-wt cells further
corroborated the DHA-effected changes in the metabolite levels.
In addition, level of glycine was also found to be elevated upon
DHA treatment. Glycine, an amino acid, is required along with
succinyl-CoA for the synthesis of porphyrins and efficient
functioning of the ETC. Our findings suggested that DHA
possibly mitigates AbPP-suppressed mitochondrial activity and
associated hypometabolism of the CHO-AbPP695 cells, thus
enabling them to recover from the metabolic perturbations.
Effect of DHA on Cholesterol Metabolism
There is a growing consensus underlying the mechanistic link
between the formation of amyloid plaques and cholesterol
metabolism [40]. Even though the effect of cholesterol on
production of Ab and metabolism is not yet completely defined,
Barrett et al recently reported that APP has a flexible transmem-
brane domain that can bind cholesterol and form an avid complex
leading to enhanced amyloidogenesis [41]. It is also believed that
the membrane cholesterol content serves as a pro-amyloidogenic
factor, governing the activity of the enzymes playing a role in
amyloidogenic processing of AbPP to Ab [42–45]. Apart from
Figure 5. DHA treatment increases pyruvate dehydrogenase
enzyme concentration in CHO-wt and CHO-AbPP695 cells.
Pyruvate dehydrogenase activity in CHO-wt and CHO-AbPP695 cells
treated with vehicle or 25 mM DHA. Values are means6 SEM from three
independent experiments. **p,0.01 and ***p,0.001 as compared to
CHO-AbPP695 vehicle treated. Analysis was done via ANOVA with
Bonferroni’s post-hoc analysis.
doi:10.1371/journal.pone.0090123.g005
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cholesterol, the oxidized products of cholesterol called oxysterols
have also been studied for their possible role in the disease
pathogenesis, due to their involvement in cholesterol regulation. In
addition, in vivo studies carried out using statins [42] and other
cholesterol lowering drugs in AD models have reported the
therapeutic effect of lowering cholesterol content in diminishing
Ab deposition and Ab load of the brain [46,47]. Increased
consumption of PUFAs (notably the omega-3 family) has been
associated with the reduction of risk in developing AD by lowering
cholesterol levels. Levels of zymosterol, a precursor to cholesterol
synthesis, and cholesta-3, 5-diene, an oxysterol, were found to be
reduced in CHO-AbPP695 cells as compared to CHO-wt with
DHA treatment. As acetyl CoA is a common precursor and link
between the TCA cycle and the cholesterol biosynthesis pathway,
the question whether more acetyl CoA is being diverted towards
energy metabolism pathways in the presence of DHA and thus
reducing its availability for cholesterol synthesis, still remains to be
answered. These results show that DHA plays a role in reducing
cholesterol biosynthesis which is a potentially AD-preventive
mechanism as demonstrated by cholesterol-lowering statins.
Effect of DHA on Fatty Acid Metabolism
The possible contribution of inflammation in the etiology and
pathogenesis of AD has been questioned over for many years now.
Several pharmacological approaches have been proposed to
control these inflammatory responses in order to prevent
destruction of the viable tissues in an AD brain. Arachidonic
acid, an omega-6 fatty acid, precursor to various pro-inflammatory
and inflammatory molecules, has been postulated to be an
important mediator of inflammation related damages in AD
[48–50]. Arachidonic acid mediated inflammation has been
reported to induce tau protein polymerization [51] and enhance
generation of reactive oxygen species. A direct role of arachidonic
acid in the pathogenesis of AD was highlighted in a study
conducted using positron emission tomography (PET) on brains of
live, non-anaesthetized humans [52], where compared to their age
matched controls, an elevated arachidonic acid metabolism was
reported in AD patients. On the contrary, endogenous level of
DHA was found to be significantly reduced in the brains of AD
patients. As DHA and its metabolites have been known to exhibit
anti-inflammatory activities, this reduction in the levels of DHA in
AD patients may lead to further aggravation of the inflammation
mediated damages in AD brain.
We found that treatment with DHA resulted in a reduction in
the endogenous levels of arachidonic acid in CHO-AbPP695 cells
as compared to CHO-wt. On the other hand, DHA levels were
found to be increased in CHO-AbPP695 cells post-treatment. This
increase in DHA levels, however, can be attributed to the
exogenous DHA treatment of the cells. Both omega-3 and omega-
6 fatty acids share the same biosynthetic pathway and compete for
pathway enzymes and incorporation into the cell membranes.
Dietary consumption of DHA would result in a displacement of
arachidonic acid from the cell membranes and serve as a precursor
for the synthesis of anti-inflammatory metabolites, such as
resolvins and protectins. Since enzymatic metabolism of arachi-
donic acid generates inflammatory mediators, decreased levels of
arachidonic acid would also imply a decrease in the generation of
its downstream metabolites and thus, a reduction in the damages
mediated by ensuing inflammation and oxidative stress.
Conclusion
GC/TOFMS-based metabonomic profiling approach served as
a sensitive and powerful tool for identification of discriminant
metabolites associated with control and DHA-treated CHO-wt
and CHO-AbPP695 cells. The metabolites identified were mainly
involved in TCA cycle, cholesterol metabolism pathway and
arachidonic acid metabolism. Our study provides an understand-
ing of the metabolic changes induced by AbPP trafficking in the
mitochondrial matrix and the mechanism by which DHA helps in
mitigating these disturbances and restores the metabolic homeo-
stasis of the mitochondria at an early stage. In addition, the
preliminary effect of DHA on cholesterol metabolism also fuels the
need to dive deeper into the mechanistic effects of DHA on the
cholesterol metabolism pathway. Considering DHA is clinically
effective in improving cognitive functions at an early stage of AD
[36,53] it may become a potential prophylactic agent for delaying
the progression of this multi-factorial disease. In the same light,
our findings will provide concurrence insights towards conceptu-
alizing effective therapeutic outcomes using DHA for the
prophylaxis of this devastating disorder.
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